Table 2.
Clinical and radiological data
| Group A | Group B | p | |
|---|---|---|---|
| Age (years) | 66 (60–71) | 67 (61–72) | 0.59 |
| PSA (ng/mL) | 7.0 (4.8–9.6) | 7.2 (5.15–9.95) | 0.49 |
| ISUP grade at radical prostatectomy | 0.46 | ||
| 1 | 1 | 0 | |
| 2 | 39 | 45 | |
| 3 | 37 | 40 | |
| 4 | 15 | 9 | |
| 5 | 9 | 6 | |
| ISUP grade at radical prostatectomy ≥ 3 | 61 | 55 | 0.47 |
| Pathologic EPE | 45 | 41 | 0.67 |
| Capsular abutment | 97 | 93 | 0.33 |
| Tumor-capsule interface (mm) | 8 (5–11) | 8 (5–12) | 0.88 |
| Tumor-capsule interface > 10 mm | 31 | 34 | 0.76 |
| Irregular or spiculated margin | 53 | 55 | 0.89 |
| Bulging prostatic contour | 37 | 35 | 0.88 |
| Asymmetry of neurovascular bundle | 13 | 12 | ≥ 0.99 |
| Measurable extraprostatic disease | 9 | 11 | 0.8 |
| Obliteration of recto-prostatic angle | 4 | 6 | 0.75 |
PSA, prostate specific antigen; ISUP, International Society of Urological Pathology; EPE, extraprostatic extension